China (Mainland)
CAS: 608141-41-9 Apremilast API/Apis C22h24n2o7s for Treating Psoriatic Arthritis CAS NO.608141-41-9
- FOB Price: USD: 1.00-2.00 /Metric Ton Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C
- Available Specifications:
EP/BP/USP(1-102)Metric TonEP/BP/USP(11-1001)Metric Ton
- Product Details
Keywords
- Apremilast
- Apremilast
- Apremilast
Quick Details
- ProName: CAS: 608141-41-9 Apremilast API/Apis C...
- CasNo: 608141-41-9
- Molecular Formula: C22h24n2o7s
- Appearance: white crystalline powder
- Application: use in chemical
- DeliveryTime: within a week
- PackAge: bags
- Port: Shanghai
- ProductionCapacity: 12 Kilogram/Day
- Purity: 99%
- Storage: Kept in a well-closed, light-resistant...
- Transportation: by sea or express
- LimitNum: 10 Gram
- Moisture Content: 0.001
- Impurity: 0.001
- Water content: 0%
Superiority
|
1,Best Quality: Our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other countries, and we have got very good feedback from our customers.so you can trust us. 2, Payment method: for example T/T, Westerm Union,other 3, Excellent Service: Best service and after-sales service to all clients. 1)We will ship the goods within 5days after get your payments.If you want to cancel or change order, please tell me within 24hours after you finish the payment.. 2)We will ship the goods that you order from us by DHL, UPS, TNT and EUB.We will decided to choose which courier depend on different countries.To find the best way to delivery the goods for you. 3)As usual you can get the goods with in 4-7days.If the goods were lost or not received for other reasons, please contact us immediately. 4,Fast and safe delivery: Sample Order : As usual you can get the goods within 4-7days. We can send it via HKems, HK Air Post, DHL or other methods. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days. Bulk Order: Shipped via sea or air, it's according to your requirement, delivery time is 7-15days after payment. We introduce experienced quality product and exceptional JIT service with instant market intelligence in China to benefit our customers and principals. With our high-performance teamwork centers and associated production sites for custom synthesis, we ensure effective professional response and offer extensive applications-related consulting and compliance regulation services. |
Details
CAS: 608141-41-9 Apremilast API/Apis C22h24n2o7s for Treating Psoriatic Arthritis
| Product Name: | Apremilast (CC-10004) |
| Synonyms: | ApreMilast;(S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide;ApreMilast,CC-10004;AcetaMide, N-[2-[(1S)-1-(3-ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-;Appleton West;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide Apremilast (CC-10004;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl) |
| CAS: | 608141-41-9 |
| MF: | C22H24N2O7S |
| Appearance: | White Powder |
| Product Categories: | Inhibitor;Inhibitors;Other series |
Description:
Apremilast (Otezla) was approved by the FDA on March 21, 2014 for the treatment of adult patients with active psoriatic arthritis. Apremilast is a member of a new class of oral small molecule inhibitors of the phosphosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in immune cells, it results in elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which can regulate inflammatory mediators. The current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.
Uses:
Treating active psoriatic arthritis. It is also used to treat moderate to severe plaque psoriasis in certain patients.
Metabolism and Drug interaction:
Oral administration of apremilast has an absolute biovailability of 73% with peak concentration at 2.5 hours (Tmax). The half-life of apremilast is 6-9 hours. Apremilast is metabolized by the both cytochrome (CYP) and non-CYP pathways. In vitro studies have demonstrated that apremilast metabolism is primarily mediated by the CYP3A4 pathway. Thus, concomitant use of apremilast with CYP450 enzyme inducers (such as rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended. There are no significant drug-drug interactions with oral contraceptives, ketoconazole, or methotrexate.
Safety information:
1.Apremilast may cause depression. The risk may be greater in patients who have a history of depression or suicidal thoughts or actions. Families and caregivers must closely watch patients who take apremilast. It is important to keep in close contact with the patient's doctor. Tell the doctor right away if the patient has new, worsened, or sudden symptoms, such as depression; anxiety, restlessness, or irritability; panic attacks; or any changes in behavior. Contact the doctor right away if any signs of suicidal thoughts or actions occur.
2.Apremilast may cause weight loss. You will need to have regular weight checks while you are taking apremilast.
COA:
| Items | Specifications | Results |
| Appearance | Off-white and white powder | Off-white powder |
| Related Substances |
Any single unknown impurity≤0.1% Total impurities:≤0.5% |
0.09% 0.13% |
| Enantiomer | <0.5% | 0.12% |
| Loss on drying | Not more than 0.5% | 0.03% |
| Melting Point | 154~158ºC | 155.6~156.7ºC |
| Residue on ignition | Not more than 0.5% | 0.01% |
| Residual solvents |
Methanol <3000ppm Ethanol <5000ppm THF<720ppm Acetone <5000ppm |
N.D. N.D. 66ppm 800ppm N.D. |
| Purity(HPLC) | ≥99.5% | 99.87% |
| Results | The product conforms to the above specifications | |